Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Drug against breast cancer is also highly potent against a frequent form of leukaemia

17.05.2016

Acute myeloid leukaemia (AML) is the most frequent form of blood cancer. In about 30 percent of all AML patients, a mutation in the FLT3 tyrosine kinase accelerates the course of the disease. Common therapies were not successful in healing these patients so far. Researchers at the University of Veterinary Medicine, Vienna managed now to specifically target and kill AML cancer cells carrying this activating mutation. They used an agent that had recently been approved for breast cancer therapy. The study was published in the top hemato-oncology journal Blood.

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body’s own safety mechanisms. To do so, cancer cells harbour mutations, which enable a continuous cellular growth.


Before treatment

Photo: Iris Uras/Vetmeduni Vienna


After treatment: The breast cancer treatment downregulates FLT3. The cancer cells die.

Photo: Iris Uras/Vetmeduni Vienna

In acute myeloid leukemia (AML), an activating mutation in the FLT3 tyrosine kinase is the most frequent mutation found in patients. According to first author Iris Uras from the Institute of Pharmacology and Toxicology at the Vetmeduni Vienna, these cancer cells depend on FLT3 – is FLT3 blocked, cancer cells die.

Common FLT3 inhibitors do not suffice to survive

Activation of signalling pathways caused by mutations in tyrosine kinases is involved in the pathogenesis of AML. Targeted pharmacological inhibition of such mutant genes holds great therapeutic potential in AML.

Because of the clinical importance of FLT3-mutations in disease progression in AML, there have been considerable efforts to develop FLT3 inhibitors which block the kinase activity and subsequently shall impair cell growth. Yet the initial great hopes have not been fulfilled and the clinical impact of FLT3 kinase inhibitors is limited. Responses in patients with FLT3 mutations have been transient and resistant clones have emerged rapidly.

Breast cancer therapeutic blocks the production of the FLT3 gene

In her study, Uras uncovered a novel therapeutic approach to treat patients with AML with FLT3 mutations. She found that another tumor-promoting factor, the enzyme CDK6, directly regulates and initiates the production of FLT3 and thus cause the disease.

The active agent developed for breast cancer treatment blocks the activity of CDK6 and subsequently downregulates FLT3. “We found a novel therapeutic window that attacks the dependency of a cancer cell on its growth regulator “, said Uras. The compound from breast cancer therapy deprives the cancer cells of “nutrients”. AML cancer cells carrying the mutation died immediately in the experiments. The drug does not affect cells lacking the mutation proving to be highly specific.

Active agent already approved

The advantage of having this agent at hand is the fact that it has already been approved for the therapy of breast cancer in 2015 – it significantly enhanced the lifespan of patients with breast cancer. Hence, clinical studies can be rapidly initiated without passing a long series of tests in advance.

A combination with compounds that block FLT3 kinase activity increases the efficacy of the breast cancer drug. The driver of the disease and as a consequence the continuous cell growth is suppressed. “We are attacking FLT3 from two sides there – blocking its expression and inhibiting its activity. A combination therapy could be a breakthrough for many patients suffering from leukaemia,” explained Uras.

About acute myeloid leukaemia

Leukaemia, also known as blood cancer, is a hematopoietic malignancy. The most frequent form is AML, acute myeloid leukaemia. Patients with AML have poor prognosis and high mortality rate despite considerable advances in chemotherapy and hematopoietic stem cell transplantations.

Service
The article „Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6“ by Iris Uras, Gina Walter, Ruth Scheicher, Florian Bellutti, Michaela Prchal-Murphy, Anca S. Tigan, Peter Valent, Florian H. Heidel, Stefan Kubicek, Claudia Scholl, Stefan Fröhling and Veronika Sexl was published in Journal Blood.
DOI: ´http://dx.doi.org/10.1182/blood-2015-11-683581
http://www.bloodjournal.org/content/early/2016/04/20/blood-2015-11-683581?sso-ch...

About the University of Veterinary Medicine, Vienna
The University of Veterinary Medicine, Vienna in Austria is one of the leading academic and research institutions in the field of Veterinary Sciences in Europe. About 1,300 employees and 2,300 students work on the campus in the north of Vienna which also houses five university clinics and various research sites. Outside of Vienna the university operates Teaching and Research Farms. http://www.vetmeduni.ac.at

Scientific Contact:
Iris Uras
Institute of Pharmacology and Toxicology
University of Veterinary Medicine Vienna (Vetmeduni Vienna)
T +43 699 182 04 603
iris.uras@vetmeduni.ac.at

Released by:
Heike Hochhauser
Corporate Communications
University of Veterinary Medicine Vienna (Vetmeduni Vienna)
T +43 1 25077-1151
heike.hochhauser@vetmeduni.ac.at

Weitere Informationen:

http://www.vetmeduni.ac.at/en/infoservice/presseinformation/presseinformationen-...

Heike Hochhauser | Veterinärmedizinische Universität Wien

Weitere Nachrichten aus der Kategorie Biowissenschaften Chemie:

nachricht Verteidigung um fast jeden Preis
14.12.2017 | Max-Planck-Institut für Evolutionsbiologie, Plön

nachricht Mitochondrien von Krebszellen im Visier
14.12.2017 | Gesellschaft Deutscher Chemiker e.V.

Alle Nachrichten aus der Kategorie: Biowissenschaften Chemie >>>

Die aktuellsten Pressemeldungen zum Suchbegriff Innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nanostrukturen steuern Wärmetransport: Bayreuther Forscher entdecken Verfahren zur Wärmeregulierung

Der Forschergruppe von Prof. Dr. Markus Retsch an der Universität Bayreuth ist es erstmals gelungen, die von der Temperatur abhängige Wärmeleitfähigkeit mit Hilfe von polymeren Materialien präzise zu steuern. In der Zeitschrift Science Advances werden diese fortschrittlichen, zunächst für Laboruntersuchungen hergestellten Funktionsmaterialien beschrieben. Die hiermit gewonnenen Erkenntnisse sind von großer Relevanz für die Entwicklung neuer Konzepte zur Wärmedämmung.

Von Schmetterlingsflügeln zu neuen Funktionsmaterialien

Im Focus: Lange Speicherung photonischer Quantenbits für globale Teleportation

Wissenschaftler am Max-Planck-Institut für Quantenoptik erreichen mit neuer Speichertechnik für photonische Quantenbits Kohärenzzeiten, welche die weltweite...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Neue Einblicke in die Materie: Hochdruckforschung in Kombination mit NMR-Spektroskopie

Forschern der Universität Bayreuth und des Karlsruhe Institute of Technology (KIT) ist es erstmals gelungen, die magnetische Kernresonanzspektroskopie (NMR) in Experimenten anzuwenden, bei denen Materialproben unter sehr hohen Drücken – ähnlich denen im unteren Erdmantel – analysiert werden. Das in der Zeitschrift Science Advances vorgestellte Verfahren verspricht neue Erkenntnisse über Elementarteilchen, die sich unter hohen Drücken oft anders verhalten als unter Normalbedingungen. Es wird voraussichtlich technologische Innovationen fördern, aber auch neue Einblicke in das Erdinnere und die Erdgeschichte, insbesondere die Bedingungen für die Entstehung von Leben, ermöglichen.

Diamanten setzen Materie unter Hochdruck

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Mit allen Sinnen! - Sensoren im Automobil

14.12.2017 | Veranstaltungen

Materialinnovationen 2018 – Werkstoff- und Materialforschungskonferenz des BMBF

13.12.2017 | Veranstaltungen

Innovativer Wasserbau im 21. Jahrhundert

13.12.2017 | Veranstaltungen

 
VideoLinks
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Was für IT-Manager jetzt wichtig ist

14.12.2017 | Unternehmensmeldung

30 Baufritz-Läufer beim 25. Erkheimer Nikolaus-Straßenlauf

14.12.2017 | Unternehmensmeldung

Mit allen Sinnen! - Sensoren im Automobil

14.12.2017 | Veranstaltungsnachrichten